Extensive prior studies have shown strong positive effects for targets and negative effects for acquirers but, they have focused on measuring value creation from individual deals, not a firm’s overall programs of activity and performance over longer time periods. This far reaching study analyzed over 20 years of data from 25,000+ global firms and 265,000+ deals.
Hear the key findings from the research and uncover the strategies of the excellent corporate portfolio managers who consistently outperform the market.
Guy Henninger, Senior Life Sciences Executive, Intralinks
Guy Henninger has many years of experience working in and with the Life Sciences industry. Guy is responsible for Intralinks’ Life Sciences business in the Northeast US and works directly with some of the largest global Pharmaceutical companies as well as numerous biotechnology and emerging Pharmaceutical companies. Guy has worked extensively with Business Development, Corporate Development and Alliance Management professionals in Life Sciences for more than 15 years. Guy brings deep subject matter expertise to his clients, ensuring that they employ the best processes, tools and techniques to get the most value from their deal making activity. Guy is a member of the Licensing Executives Society and Association of Strategic Alliance Professionals, and has been a guest lecturer at the St Joseph’s University Pharmaceutical Executive MBA program.
James Whitehurst, Program Manager, Intralinks
James Whitehurst currently works in the Intralinks marketing department, his current focus is Intralinks’ Financial Services sector. His responsibilities within this include, content delivery and planning and executing marketing campaigns globally. He has presented research findings at numerous international M&A conferences, including MergerMarket conferences in Milan, Venice, and Amsterdam. He holds a BSc from University College London, and a Masters in Finance from the University of London.
Ben Bonifant, Partner, Triangle Insights Group, LLC
Ben Bonifant is an experienced consultant to leaders of global Pharmaceutical and biotechnology organizations, and to decision makers of large private equity funds. Ben has been a management consultant for more than twenty years. His perspectives on developments in the life sciences market are frequently published in industry and strategy journals.
Recent by-lined articles have appeared in Pharmaceutical Executive, InVivo, Nature Biotech, RPM Report, and Scrip. In addition, Ben’s case studies on the Pharmaceutical industry have been used in graduate business programs. Ben is a past chair of the Life Sciences Executive Committee of the Licensing Executive Society. He has also been a member of the program committee for the BIO International Convention. Prior to the founding of Triangle Insights Group,
Ben was the leader of the Business Development Practice at Campbell Alliance and a partner in the Strategy practice at Oliver Wyman (formerly Mercer Management Consulting/Strategic Planning Associates). Ben has been a guest lecturer at Duke’s Fuqua School of Business, the Indiana University Kelley School of Business, and industry conferences in the US, Europe, and Canada. Ben earned an M.B.A. from the Stanford Graduate School of Business and a B.S. from Duke University.
Who Should Attend?
- Drug Safety Leaders
- Chief Medical Officers
- Chief Executive Officers
- Business Development Leaders
Intralinks is changing how we think about secure collaboration by reinventing the way companies do business externally.
Access and share secure documents anytime, anywhere, and from any device. Intralinks gives you the freedom to work beyond boundaries — and the security to do so with absolute confidence.
Discover how we’re helping sponsors and CRO’s revolutionize their clinical trial processes by providing HIPAA-complaint virtual workspaces to investigator sites for them to control and which enable remote monitoring – even of non-redacted patient information.